Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BB Biotech AGXSWX:BION +0.56%33 Cash-to-Debt is No Debt (1) as of Jun. 2026, which is 100% below its 10-year median of 0.02. GuruFocus rates XSWX:BION with a GF Score™ of 33/100. The stock has 3 warning signs investors should review. Among 1,400 Biotechnology companies, BB Biotech AG ranks better than 99.71% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. BB Biotech AG's cash to debt ratio for the quarter that ended in Jun. 2026 was No Debt (1).
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, BB Biotech AGcould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
The historical rank and industry rank for BB Biotech AG's Cash-to-Debt or its related term are showing as below:
XSWX:BION'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0 Med: 0.02 Max: No Debt
Current: No Debt
During the past 13 years, BB Biotech AG's highest Cash to Debt Ratio was No Debt. The lowest was 0.00. And the median was 0.02.
XSWX:BION's Cash-to-Debt is ranked better than 99.71% of 1400
companies
in the Biotechnology industry
Industry Median: 6.21
vs XSWX:BION: No Debt
BB Biotech AG (XSWX:BION) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
BB Biotech AG Cash-to-Debt Related Terms
BB Biotech AG Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for BB Biotech AG's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
XSWX:BION vs VRTX, REGN, RVMD: Cash-to-Debt Comparison
For the Biotechnology subindustry, BB Biotech AG's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BB Biotech AG Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BB Biotech AG's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where BB Biotech AG's Cash-to-Debt falls into.
BB Biotech AG's Cash to Debt Ratio for the fiscal year that ended in Dec. 2025 is calculated as:
BB Biotech AG had no debt (1).
BB Biotech AG's Cash to Debt Ratio for the quarter that ended in Jun. 2026 is calculated as:
BB Biotech AG had no debt (1).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash-to-Debt of No Debt <sup>(1)</sup> mean?
BB Biotech AG (XSWX:BION) has a Cash-to-Debt of No Debt (1) as of Jun. 2026. This is 4900% above median its historical median of 0.02. According to the industry distribution chart, BB Biotech AG ranks #4 out of 1400 companies in the Biotechnology industry, placing it in the top 0.3%.
Is BB Biotech AG's Cash-to-Debt too high?
BB Biotech AG's current Cash-to-Debt of No Debt (1) is 4900% above median its 10-year median of 0.02. Based on the distribution chart, BB Biotech AG ranks #4 out of 1400 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BB Biotech AG has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does BB Biotech AG's Cash-to-Debt compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BB Biotech AG ranks #4 out of 1400 companies for Cash-to-Debt. This places BB Biotech AG in the top 0% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 6.21. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.21, based on 1,400 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BB Biotech AG's current Cash-to-Debt is No Debt (1), which is 4900% above median its own 10-year median of 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BB Biotech AG stock overvalued right now?
BB Biotech AG (XSWX:BION) has a current Cash-to-Debt of No Debt (1). The current Cash-to-Debt is No Debt (1), which is 4900% above median its 10-year median of 0.02. BB Biotech AG's overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For BB Biotech AG (XSWX:BION), the current Cash-to-Debt is No Debt (1) as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments, especially in the biotechnology market, and is one of the investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the healthcare system. Geographically company operates in the USA, Netherlands, Singapore, Great Britain, Canada, Switzerland, Curacao, and British Virgin Island.
33GF Score
Get the complete analysis for XSWX:BION
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BION has been successfully added to your 
